<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227458</url>
  </required_header>
  <id_info>
    <org_study_id>16-2427</org_study_id>
    <secondary_id>R01AG053489</secondary_id>
    <nct_id>NCT03227458</nct_id>
  </id_info>
  <brief_title>DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women</brief_title>
  <official_title>DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the musculoskeletal adaptations to bone-loading exercise can be&#xD;
      significantly augmented in older women (aged 60-85) with low bone mass (osteopenia; T-scores&#xD;
      &lt;-1.0 and &gt;-2.5) or moderate osteoporosis (T-scores &lt; -2.5 and &gt;= -3.0) and by restoring&#xD;
      serum DHEAS to young adult levels by oral DHEA replacement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be the first study to measure changes in areal bone mineral density (aBMD) and&#xD;
      fat-free mass (FFM) in response to dehydroepiandrosterone (DHEA) alone and combined with&#xD;
      exercise in postmenopausal women. The body of evidence from carefully executed Randomized&#xD;
      Controlled Studies (RCTs) provides support for DHEA therapy to increase aBMD and FFM in older&#xD;
      women. Less is known about whether DHEA therapy enhances the effects of exercise on the aging&#xD;
      musculoskeletal system when an appropriate mechanical stimulus is applied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will take 1 study pill (50 mg DHEA or placebo: double-blinded) daily for 36 weeks. The research pharmacist will dispense study drug according to the randomization code and maintain drug dispensation records, which will be monitored by the study biostatistician. Two-thirds of participants will engage in bone-loading exercise 3 days per week for the 36 weeks.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Study drug will be masked. 50 mg DHEA or placebo: double-blinded. Exercise will not be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lumbar spine aBMD</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in lumbar spine aBMD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total hip aBMD</measure>
    <time_frame>36 Weeks</time_frame>
    <description>mean change from baseline in total hip aBMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in regional hip aBMD</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in regional hip aBMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vertebral (L1-2) total volumetric bone mineral density (vBMD)</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in vertebral total volumetric BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vertebral (L1-2) cortical vBMD</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in vertebral cortical volumetric BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vertebral (L1-2) trabecular vBMD</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in vertebral trabecular volumetric BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Femoral total vBMD</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in femoral total volumetric BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Femoral cortical vBMD</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in femoral cortical volumetric BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Femoral trabecular vBMD</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in femoral trabecular volumetric BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vertebral (L1-2) strength, stance model</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in the estimated strength of L1-2 vertebrae in a stance model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vertebral (L1-2) strength, fall model</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in the estimated strength of L1-2 vertebrae in a fall model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proximal femur strength, stance model</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in the estimated strength of the proximal femur in a stance model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proximal femur strength, fall model</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in the estimated strength of the proximal femur in a fall model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total body fat-free mass</measure>
    <time_frame>Baseline and 36 Weeks</time_frame>
    <description>mean change from baseline in total body fat-free mass</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Low Bone Mass</condition>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Exercise and DHEA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise and Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHEA only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 study pill containing 50 mg of DHEA daily for 36 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DHEA</intervention_name>
    <description>Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.</description>
    <arm_group_label>DHEA only</arm_group_label>
    <arm_group_label>Exercise and DHEA</arm_group_label>
    <other_name>DHEA therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will take placebo daily for 36 weeks.</description>
    <arm_group_label>Exercise and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>bone-loading exercise on 3 days per week for 38 weeks</description>
    <arm_group_label>Exercise and DHEA</arm_group_label>
    <arm_group_label>Exercise and Placebo</arm_group_label>
    <other_name>bone-loading exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  non-frail, as determined by short physical performance battery (SPPB) score &gt; 9 (0-12&#xD;
             scale);&#xD;
&#xD;
          -  5 years or longer since menopause (defined as last menstrual period);&#xD;
&#xD;
          -  willing to participate in a 36-week exercise program that will start at a moderate&#xD;
             intensity and gradually progress to a higher intensity;&#xD;
&#xD;
          -  willing to be randomized to an exercise or a no-exercise arm of the study;&#xD;
&#xD;
          -  willing to take DHEA (50mg/d) or a placebo pill daily and remain blinded for up to 36&#xD;
             weeks;&#xD;
&#xD;
          -  not performing resistance exercise training or high impact weight-bearing exercise&#xD;
             (e.g., jogging) ≥ 2 days per week in the past 6 months;&#xD;
&#xD;
          -  ambulatory without assistive devices;&#xD;
&#xD;
          -  serum DHEAS &lt; 140 μg/dL (3.8 μmol/L);&#xD;
&#xD;
          -  low bone mass or moderate osteoporosis defined as lumbar spine or proximal hip aBMD&#xD;
             t-scores &lt; -1.0 and &gt; = -3.0;&#xD;
&#xD;
          -  evidence of a negative (no findings suspicious for breast cancer) mammogram within the&#xD;
             past 12 months;&#xD;
&#xD;
          -  planning to reside in the Denver area for the duration of the study&#xD;
&#xD;
          -  normal cognitive function, as determined by a Mini-Cog score &gt; = 4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of hospitalization for Corona Virus Disease-19 (COVID-19)&#xD;
&#xD;
          -  does not meet Centers for Disease Control and Prevention (CDC) recommendations for&#xD;
             home isolation because has had a positive severe acute respiratory syndrome corona&#xD;
             virus-2 (SARS-COV-2) test less than 10 days before study entry; or has had fever&#xD;
             within the past 3 days and respiratory symptoms have not improved; or symptoms first&#xD;
             appeared less than 10 days before study entry&#xD;
&#xD;
          -  uncontrolled hypertension defined as resting systolic blood pressure (sBP) &gt;150 mmHg&#xD;
             or diastolic blood pressure (dBP) &gt;90 mmHg; participants who do not meet these&#xD;
             criteria at first screening will be re-evaluated, including follow-up evaluation by&#xD;
             their Primary Care Physician (PCP) with initiation or adjustment of anti-hypertensive&#xD;
             medications;&#xD;
&#xD;
          -  diagnosed ischemic heart disease or indicators of unstable ischemic heart disease&#xD;
             (e.g., angina, ST segment depression) or arrhythmias at rest or during the Gated&#xD;
             Exercise Test (GXT) without negative follow-up evaluation will be cause for exclusion;&#xD;
             follow-up evaluation must include diagnostic testing (e.g., thallium stress test) with&#xD;
             interpretation by a cardiologist;&#xD;
&#xD;
          -  diagnosis of heart failure, clinically significant aortic stenosis, uncontrolled&#xD;
             angina, or uncontrolled arrhythmia.&#xD;
&#xD;
          -  pulmonary disease requiring use of oral steroids within the previous 6 months or the&#xD;
             use of supplemental oxygen ≥ 4 liters with physical exertion&#xD;
&#xD;
          -  orthopedic problems (e.g., severe osteoarthritis, rheumatoid arthritis) that greatly&#xD;
             limit the ability to perform moderate to high intensity resistance exercise (e.g.,&#xD;
             unable to be properly positioned in exercise equipment or to have severely restricted&#xD;
             range of motion even after modifications have been made)&#xD;
&#xD;
          -  hip fracture, hip or knee replacement, or spinal surgery in the past 6 months;&#xD;
&#xD;
          -  undergoing physical therapy involving the lower extremities;&#xD;
&#xD;
          -  hematocrit (HCT) &gt; 54%;&#xD;
&#xD;
          -  thyroid dysfunction, defined as an ultrasensitive thyroid stimulating hormone (TSH) &lt;&#xD;
             0.4 or &gt; 10.0 microunits/mL;, without signs or symptoms of clinical hypo- or&#xD;
             hyperthyroidism. Volunteers with abnormal TSH values will be re-considered for&#xD;
             participation in the study after follow-up evaluation by their PCP with initiation or&#xD;
             adjustment of thyroid hormone replacement;&#xD;
&#xD;
          -  acute liver disease indicated by liver function tests (alanine aminotransferase (ALT),&#xD;
             aspartate aminotransferase (AST), alkaline phosphatase) ≥ 1.5 times the upper limits&#xD;
             of normal;&#xD;
&#xD;
          -  estimated glomerular filtration rate (eGFR) &lt; 45, using the Modification of Diet in&#xD;
             Renal Disease (MDRD) equation (Levey et al, Annals Inter Med, 1999; Munter et al, Clin&#xD;
             J Am Soc Nephol, 2009);&#xD;
&#xD;
          -  poorly controlled diabetes mellitus based on HbA1c &gt; 8.5%, or use of insulin;&#xD;
&#xD;
          -  fasted serum triglycerides &gt; 400 mg/dL;&#xD;
&#xD;
          -  serum 25-hydroxy vitamin D &lt;20 ng/mL; volunteers will be re-considered for&#xD;
             participation in the study after follow-up evaluation by their PCP with initiation or&#xD;
             adjustment of vitamin D supplementation per the study's vitamin D repletion protocol.&#xD;
&#xD;
          -  use of DHEA supplementation or sex hormones in the past 6 months. Use of prescription&#xD;
             low dose vaginal estrogen creams (Premarin or Estrace) 3 days per week will not be&#xD;
             exclusionary.&#xD;
&#xD;
          -  use in the past 6 months of any medications known to alter bone metabolism (e.g., oral&#xD;
             glucocorticoids, bone anti-resorptive agents);&#xD;
&#xD;
          -  documented history of cognitive impairment or dementia, or Mini-Cog &lt; 4;&#xD;
&#xD;
          -  current smoker;&#xD;
&#xD;
          -  personal history of breast, ovarian, metastatic endometrial, or cervical cancer;&#xD;
&#xD;
          -  any cancer requiring treatment in the past 3 years except non-melanoma skin cancers;&#xD;
&#xD;
          -  un-diagnosed vaginal bleeding;&#xD;
&#xD;
          -  women who, in the judgment of the study physician, appear incapable of safely&#xD;
             participating in the exercise (e.g., neuromuscular/musculoskeletal impairment)&#xD;
&#xD;
          -  use of insulin.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Jankowski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Jankowski, PhD</last_name>
    <phone>303-724-7383</phone>
    <email>catherine.jankowski@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Jankowski, PhD</last_name>
      <phone>303-724-7383</phone>
      <email>catherine.jankowski@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine Jankowski, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>areal bone mineral density</keyword>
  <keyword>dehydroepiandrosterone (DHEA)</keyword>
  <keyword>postmenopause</keyword>
  <keyword>exercise</keyword>
  <keyword>sex hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

